Not so puzzling: Actavis, Forest pieces fit strategic gaps

The $25bn merger of brand-name drug marketer Forest Laboratories into generics maker Actavis isn't so puzzling, considering Actavis's increased focus on specialty medicines and the pent-up demand for significant returns for Forest shareholders.